Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Sees Further FDA Action On Prograf MR In Early 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.

You may also be interested in...



Astellas Responds To "Approvable" Letter For Prograf MR Kidney Transplant Claim

Astellas Pharma has responded to an FDA "approvable" letter for use of the once-daily immunosuppressant Prograf MR (tacrolimus modified-release) to prevent rejection of kidney transplants, the Japanese firm announced Sept. 19

Astellas Responds To “Approvable” Letter For Prograf MR Kidney Transplant Claim

Tokyo-based pharma is still examining what action to take regarding a “not approvable” letter for a heart transplant indication.

Astellas Responds To “Approvable” Letter For Prograf MR Kidney Transplant Claim

Tokyo-based pharma is still examining what action to take regarding a “not approvable” letter for a heart transplant indication.

Related Content

Topics

UsernamePublicRestriction

Register

PS066426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel